Table 4.
Reasons for stavudine/lamivudine/nevirapine (d4T/3TC/NVP) treatment change and duration of treatment
| Reason for treatment change | No. (%) | Days on treatment [median (range)] | No. (%) who stopped treatment permanently* |
|---|---|---|---|
|
| |||
| Total | 131 (100) | 262 (2–1519) | 15 (11.5) |
| Adverse effects | 82 (62.6) | 295 (2–1519) | 2 (2.4) |
| Lipodystrophy | 26 (31.7) | 546 (30–1519) | 0 (0.0) |
| Hepatitis | 10 (12.2) | 27.5 (14–1297) | 0 (0.0) |
| Rash | 12 (14.6) | 14 (10–108) | 0 (0.0) |
| Peripheral neuropathy | 9 (11.0) | 407 (117–532) | 0 (0.0) |
| Lactic acidosis | 6 (7.3) | 416 (204–951) | 0 (0.0) |
| Pancreatitis | 5 (6.1) | 55 (5–343) | 1 (20.0) |
| Nausea and vomiting | 4 (4.9) | 17.5 (2–49) | 0 (0.0) |
| Fever | 2 (2.4) | 19 (11–27) | 0 (0.0) |
| Allergy | 1 (1.2) | 61 | 0 (0.0) |
| Insomnia | 1 (1.2) | 42 | 0 (0.0) |
| Missing | 6 (7.3) | 67.5 (21–491) | 1 (16.7) |
| Patient’s decision/request | 18 (13.7) | 195.5 (6–1005) | 7 (38.9) |
| Treatment failure | 5 (3.8) | 457 (138–672) | 0 (0.0) |
| Clinical progression/hospitalization | 3 (2.3) | 85 (34–322) | 1 (33.3) |
| Compliance difficulties | 2 (1.5) | 135.5 (9–262) | 0 (0.0) |
| Other | 18 (13.7) | 250 (13–1071) | 4 (22.2) |
| Financial problem | 3 (16.7) | 467 (264–549) | 1 (33.3) |
| Doctor’s decision | 2 (11.1) | 809 (547–1071) | 0 (0.0) |
| Pregnancy | 2 (11.1) | 646.5 (286–1007) | 0 (0.0) |
| Lost to follow up | 1 (5.6) | 29 | 0 (0.0) |
| Patient died | 1 (5.6) | 236 | 1 (100) |
| Not specified | 9 (50.0) | 155 (13–415) | 2 (22.2) |
| Not reported | 3 (2.3) | 211 (88–545) | 1 (33.3) |
*
As a percentage of the total number of patients who changed treatment for a specific reason (in the second column).